GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inter Pharma PCL (BKK:IP) » Definitions » Short-Term Debt & Capital Lease Obligation

Inter Pharma PCL (BKK:IP) Short-Term Debt & Capital Lease Obligation : ฿266 Mil (As of Mar. 2025)


View and export this data going back to 2019. Start your Free Trial

What is Inter Pharma PCL Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. Inter Pharma PCL's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was ฿266 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Inter Pharma PCL's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was ฿232 Mil.


Inter Pharma PCL Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Inter Pharma PCL's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inter Pharma PCL Short-Term Debt & Capital Lease Obligation Chart

Inter Pharma PCL Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Short-Term Debt & Capital Lease Obligation
Get a 7-Day Free Trial 26.97 166.99 151.67 139.42 161.73

Inter Pharma PCL Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Short-Term Debt & Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 135.16 100.48 153.20 161.73 266.30

Inter Pharma PCL Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.


Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term


Inter Pharma PCL Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Inter Pharma PCL's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.


Inter Pharma PCL Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inter Pharma PCL (BKK:IP) » Definitions » Short-Term Debt & Capital Lease Obligation
Traded in Other Exchanges
N/A
Address
Silom Road, 140/9 ITF Tower 9th Floor, Suriyawongse, Bangrak, Bangkok, THA, 10500
Inter Pharma PCL is a biopharmaceutical company. It is engaged in the import, manufacture and distribution of drug, and dietary supplement products for humans and animals. It offers products related to Wellness and Anti-aging, Aesthetics, Diagnostics, Vitamins, and other products. The company operates in three reportable segments Human healthcare, Animal Healthcare, and Hospital and clinics in Thailand. Key revenue is derived from the Human healthcare segment.